Research - Tekmira Pharmaceuticals (TKMR) continues to recast itself as a pipeline, product-focused company, steering away from investors’ long-time perception of the Canadian firm as a developer … Continue Reading
PremiumInsights - Neuralstem (CUR) announced a $19.65M registered direct offering on Friday morning. Recall that Jason Napodano of Zacks Small-Cap Research has covered Neuralstem at length for … Continue Reading
Read nowInsights - It’s been a banner year in biotech, and one of PropThink’s top picks in 2013, Keryx Biopharmaceuticals (KERX), has outperformed significantly as one of the … Continue Reading
Read nowResearch - Progenics Pharmaceuticals (PGNX) listed a new trial on clinicaltrials.gov on Monday that supports the PGNX long thesis. The stock has a had a nice run this … Continue Reading
PremiumInsights - Endocyte (ECYT) on Monday filed to sell $60 million in common stock through an At The Market sales agreement with Cowen and Company. PropThink discussed ECYT at length here and here. … Continue Reading
PremiumInsights - On Monday after the close, Cempra (CEMP) updated investors on its pipeline progress. We saw no major surprises and consider the update net-neutral, if not –positive. Read … Continue Reading
Read nowResearch - Although the stock is getting away from us as we await feedback from the company (more below), for those not already involved, Progenics (PGNX) is … Continue Reading
Premium
